MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/2643-3230.bcd-24-0354

Медицинская библиотека · Blood cancer discovery · 2025

Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Razzo Beatrice M, Midha Shonali, Portuguese Andrew J, Grajales-Cruz Ariel F, De Menezes Silva Corraes Andre, Costello Patrick, Liu Yuxin, Sperling Adam S, Nadeem Omar, Dima Danai, Banerjee Rahul, Cowan Andrew J, Afrough Aimaz, Anderson Larry D, Lieberman-Cribbin Alex, Kaur Gurbakhash, Goyal Anmol, Atrash Shebli, Ferreri Christopher J, Voorhees Peter M, Pasvolsky Oren, Lee Hans C, Patel Krina K, Julian Kelley L, Forsberg Peter A, Herr Megan M, Chhabra Saurabh, Parrondo Ricardo D, Lin Yi, Chen Anna, Susanibar-Adaniya Sandra P, Khouri Jack, Raza Shahzad, Anwer Faiz, Vazquez-Martinez Mariola, Castaneda Puglianini Omar, Sborov Douglas W, Davis James A, Rossi Adriana, Shune Leyla, Bhurtel Jenny, Hwang Wei-Ting, Hansen Doris K, Sidana Surbhi, Garfall Alfred L, Richard Shambavi

СтатьяПеревод в очереди

Аннотация

UNLABELLED: Teclistamab is an anti-CD3-/B-cell maturation antigen (BCMA) bispecific antibody approved for use in relapsed/refractory multiple myeloma. We undertook a retrospective study of post-approval, real-world outcomes with teclistamab in the US Multiple Myeloma Immunotherapy Consortium. Among 509 patients, 89% would have been ineligible for the MajesTEC-1 trial, primarily due to prior BCMA-directed therapy, cytopenias, or diminished performance status. Cytokine release syndrome occurred in 54% (1.4% grade ≥3) and immune effector cell-associated neurotoxicity syndrome in 11% (2.2% grade ≥3), with no fatal events. Infections occurred in 42% and contributed to death in 5%. Partial response (PR) or better was achieved in 53% and very good PR or better in 45%. With 10.1 months of median follow-up, the estimated median progression-free survival (PFS) was 5.8 months and 12-month overall survival was 61%. Independent predictors of less than very good PR and shorter PFS included BCMA-directed chimeric antigen receptor T-cell therapy in the previous 9 months, high disease burden, lymphopenia, and elevated ferritin.

SIGNIFICANCE: T cell-engaging bispecific antibodies such as teclistamab represent an important new treatment modality for multiple myeloma and other blood cancers. This study evaluates the real-world safety and efficacy of teclistamab, including its activity in populations not represented in the initial phase I/II study, and identifies clinical variables associated with treatment response. See related commentary by Zweegman et al., p. 542.

Для цитирования: Razzo Beatrice M, Midha Shonali, Portuguese Andrew J, Grajales-Cruz Ariel F, De Menezes Silva Corraes Andre, Costello Patrick, Liu Yuxin, Sperling Adam S, Nadeem Omar, Dima Danai, Banerjee Rahul, Cowan Andrew J, Afrough Aimaz, Anderson Larry D, Lieberman-Cribbin Alex, Kaur Gurbakhash, Goyal Anmol, Atrash Shebli, Ferreri Christopher J, Voorhees Peter M, Pasvolsky Oren, Lee Hans C, Patel Krina K, Julian Kelley L, Forsberg Peter A, Herr Megan M, Chhabra Saurabh, Parrondo Ricardo D, Lin Yi, Chen Anna, Susanibar-Adaniya Sandra P, Khouri Jack, Raza Shahzad, Anwer Faiz, Vazquez-Martinez Mariola, Castaneda Puglianini Omar, Sborov Douglas W, Davis James A, Rossi Adriana, Shune Leyla, Bhurtel Jenny, Hwang Wei-Ting, Hansen Doris K, Sidana Surbhi, Garfall Alfred L, Richard Shambavi. Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.. Blood cancer discovery. 2025. DOI: 10.1158/2643-3230.bcd-24-0354.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.